Non-cardiomyocyte microRNAs in heart failure

Cardiovascular Research

Volumn 93, Issue 4, 2012, Pages 573-582

  Tijsen, Anke J ^a   Pinto, Yigal M ^a   Creemers, Esther E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Fibrosis; Heart failure; Inflammation; miRNAs

Indexed keywords

MICRORNA;

APOPTOSIS; CAPILLARY DENSITY; DISEASE COURSE; ENDOTHELIUM CELL; FIBROBLAST; FIBROSING ALVEOLITIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBROBLASTS; FIBROSIS; HEART FAILURE; HUMANS; MICRORNAS; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84857972864     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr344     Document Type: Review

References (86)

1. Creemers EE, Wilde AA, Pinto YM. Heart failure: advances through genomics. Nat Rev Genet 2011;12:357-362.
2. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009;105:1164-1176.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116: 281-297.
4. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005;120:21-24. (Pubitemid 40094599)
5. van Rooij E, Olson EN. microRNAs put their signatures on the heart. Physiol Genom 2007;31:365-366. (Pubitemid 350127776)
6. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008;105:2111-2116. (Pubitemid 351439473)
7. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008;118:1567-1576.
8. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-618. (Pubitemid 46828487)
9. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
10. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA et al. The endothelialspecific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-271.
11. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011;89:265-272.
12. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011;89:744-753.
13. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010;87:431-439.
14. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008;454:56-61. (Pubitemid 351931982)
15. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007;100: 1164-1173. (Pubitemid 46684129)
16. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103:18255-18260. (Pubitemid 44871645)
17. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 2010;39: 373-384.
18. van Rooij E. The art of microRNA research. Circ Res 2011;108:219-234.
19. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-689.
20. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA et al. Stressdependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010;120:3912-3916.
21. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899. (Pubitemid 351550859)
22. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82:21-29.
23. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207:1589-1597.
24. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 2011;301:F793-801.
25. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011;22:1668-1681.
26. Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, Kanakamedala K et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA 2011;108:10144-10149.
27. Thum T, Chau N, Bhat B, Gupta SK, Linsley PS, Bauersachs J et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest 2011;121: 461-462.
28. Obad S, Dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43:371-378.
29. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010;285:20281-20290.
30. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009;284:29514-29525.
31. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-13032.
32. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16:23-29.
33. Long J,Wang Y,WangW, Chang BH, Danesh FR. MicroRNA-29c is a signature micro-RNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 2011;286: 11837-11848.
34. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 2010;55:946-952.
35. Li Q, Lin X, Yang X, Chang J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am J Physiol Heart Circ Physiol 2010;298: H1340-H1347.
36. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-3254.
37. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of micro-RNAs in myocardial matrix remodeling. Circ Res 2009;104:170-178, 6p.
38. Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai B et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009;83:465-472.
39. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010;106:166-175.
40. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003;83:59-115. (Pubitemid 36459878)
41. Boak L, Chin-Dusting JP. Hypercholesterolemia and endothelium dysfunction: role of dietary supplementation as vascular protective agents. Curr Vasc Pharmacol 2004;2: 45-52. (Pubitemid 38855014)
42. MacCarthy PA, Shah AM. Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. Circulation 2000;101: 1854-1860. (Pubitemid 30213109)
43. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008;118:818-827.
44. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-126. (Pubitemid 39004240)
45. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47:887-893. (Pubitemid 44297560)
46. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001;98:5780-5785. (Pubitemid 32435719)
47. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59-68. (Pubitemid 47094624)
48. Wang S, Olson EN. AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 2009;19:205-211.
49. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-284.
50. Zou J, Li WQ, Li Q, Li XQ, Zhang JT, Liu GQ et al. Two functional microRNA-126s repress a novel target gene p21-activated kinase 1 to regulate vascular integrity in zebrafish. Circ Res 2011;108:201-209.
51. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009;324:1710-1713.
52. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010;115:4944-4950.
53. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C,Wentzel E et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38: 1060-1065. (Pubitemid 44325933)
54. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10:769-779.
55. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875-886. (Pubitemid 351312807)
56. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One 2011;6:e16979.
57. Sabatel C, Cornet AM, Tabruyn SP, Malvaux L, Castermans K, Martial JA et al. Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Mol Cancer 2010;9:231.
58. Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q et al. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21- dependent mechanism. Circ Res 2010;107:138-143.
59. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN,Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23, 27, 24 clusters. Proc Natl Acad Sci USA 2011;108:8287-8292.
60. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011;124: 720-730.
61. Qian L, Van Laake LW, Huang Y, Liu S,WendlandMF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med 2011;208:549-560.
62. Ivan M, Harris AL, Martelli F, Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med 2008;12:1426-1431.
63. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283:15878-15883.
64. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010;122:S124-S131.
65. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 2009;284:33161-33168.
66. Dentelli P, Rosso A, Orso F, Olgasi C, Taverna D, Brizzi MF. microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol 2010;30:1562-1568.
67. Chen Y, Banda M, Speyer CL, Smith JS, Rabson AB, Gorski DH. Regulation of the expression and activity of the antiangiogenic homeobox gene GAX/MEOX2 by ZEB2 and microRNA-221. Mol Cell Biol 2010;30:3902-3913.
68. Small EM, Sutherland LB, Rajagopalan KN, Wang S, Olson EN. MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling. Circ Res 2010;107: 1336-1344.
69. Grundmann S, Hans FP, Kinniry S, Heinke J, Helbing T, Bluhm F et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation 2011;123:999-1009.
70. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008;45:185-192.
71. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-479. (Pubitemid 27110479)
72. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JWet al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J AmColl Cardiol 1996;28:964-971. (Pubitemid 26348163)
73. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;2:243-249.
74. Ha T, Liu L, Kelley J, Kao R, Williams D, Li C. Toll-like receptors: new players in myocardial ischemia/reperfusion injury. Antioxid Redox Signal 2011;15:1875-1893.
75. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170:1831-1840. (Pubitemid 47339258)
76. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011;3:159-166.
77. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-12486. (Pubitemid 44267285)
78. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010;87:656-664.
79. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007;104:1604-1609. (Pubitemid 46214637)
80. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608-611. (Pubitemid 46683148)
81. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007;282:24262-24269. (Pubitemid 47328062)
82. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-147.
83. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110: in press.
84. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.
85. Tijsen AJ, Creemers EE, Moerland PD, De Windt LJ, van der Wal AC, Kok WE et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010;106:1035-1039.
86. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201.